ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Pharmacoepidemiology"

  • Abstract Number: 0534 • ACR Convergence 2020

    National Variation and Factors Associated with Long-term Opioid Use for Non-cancer Pain in the First Year of Use

    Meghna Jani1, Belay Yimer1, Therese Sheppard1, Mark Lunt1 and William Dixon1, 1Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom

    Background/Purpose: Physician prescribing behaviour has been described as a key driver of rising opioid prescriptions and long-term opioid use. However, the effect of prescribers requires…
  • Abstract Number: 0550 • ACR Convergence 2020

    Mapping Multimorbidity Using Drug Concept Unique Identifiers (RxCUIs) via the Rx-Risk Comorbidity Index

    Jared Vanderbleek1, Justin Owensby1, Alex Mccannaly1, Lang Chen1, Bryant England2, Jeffrey R Curtis3 and Huifeng Yun3, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Nebraska Medical Center, Omaha, NE, 3Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Identifying and accurately classifying comorbid conditions in large, real-world data sources is crucial for cohort establishment and confounder adjustment. However, the ability to conduct…
  • Abstract Number: 0594 • ACR Convergence 2020

    Mechanical and Temperature Stress During Biologic Shipments to Rheumatology Patients

    Sarah Dill1, Elizabeth Cheng2, Kyle Brees2, John Carpenter3 and Liron Caplan2, 1University of Colorado, Denver, CO, 2Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO, 3University of Colorado Skaggs School of Pharmacy, Aurora, CO

    Background/Purpose: Biologic medications are expensive, and unfortunately their immunogenicity contributes to loss of efficacy over time. Protein particles may form as a result of medication…
  • Abstract Number: 1122 • ACR Convergence 2020

    Osteoarthritis in a Large Integrated Health System Population: 18-Year Retrospective Review

    Jove Graham1, Tonia Novosat1, Haiyan Sun1, Brian Piper2, Joseph Boscarino1, Melissa Kern1, Vanessa Duboski3, Eric Wright3, Patricia Schepman4, Rebecca Robinson5, Edward Casey6, Craig Beck7 and Jerry Hall8, 1Geisinger, Danville, 2Geisinger, Scranton, 3Geisinger, Forty Fort, 4Pfizer, New York City, NY, 5Eli Lilly and Company, Indianapolis, 6Pfizer, New York, 7Pfizer, London, 8Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Osteoarthritis (OA) is a mechanically and immunologically mediated common disease with a complex pathogenesis.  Despite epidemiologic studies proving increasing age, obesity and female gender…
  • Abstract Number: 1481 • ACR Convergence 2020

    A Systematic Review to Quantify the Extent of Pharmaceutical Company Involvement in Rheumatology Consensus-Based Recommendations

    Dominique Feterman Jimenez1, Garret Duron2, Ali Duarte-Garcia3, Paul Sufka4, Samuel Whittle5, Philip Robinson6, Larry Prokop3 and Michael Putman7, 1UConn Health Center, Farmington, CT, 2HCA Memorial Health University Medical Center, Savannah, GA, 3Mayo Clinic, Rochester, MN, 4Healthpartners, St Paul, 5Rheumatology Unit, The Queen Elizabeth Hospital, Springfield, South Australia, Australia, 6University of Queensland, Herston, Queensland, Australia, 7Northwestern University, Chicago, IL

    Background/Purpose: Consensus-based recommendations guide standards of care for clinical practice. Pharmaceutical-industry involvement in producing such recommendations may undermine their objectivity. We performed a systematic review…
  • Abstract Number: 1570 • ACR Convergence 2020

    Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology

    Amy Cunningham-Bussel1, Jiaqi Wang1, Lauren C. Prisco2, Lily Martin2, Lydia Gedmintas1, Lindsey Macfarlane1, Nancy Shadick1, Mark Awad3, Osama Rahma3, Nicole LeBoeuf3, Ellen Gravallese1 and Jeffrey Sparks1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, 3Dana-Farber Cancer Institute, Boston, MA

    Background/Purpose: Immune checkpoint inhibitors (ICI) are used to treat an expanding number of cancers. Many cancer patients treated with ICI develop immune-related adverse events (irAE)…
  • Abstract Number: 1637 • ACR Convergence 2020

    Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan

    Jun Shimizu1, Yoshihisa Yamano1, Kimito Kawahata2 and Noboru Suzuki1, 1St. Marianna University School of Medicine, Kawasaki, Japan, 2Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: We conducted a retrospective survey study in 2009 and collected clinical data of 239 patients with relapsing polychondritis (RP). Using the survey data, we…
  • Abstract Number: 1993 • ACR Convergence 2020

    Cardiovascular Risk in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine

    Mengdong He1, Ajinkya Pawar1, Rishi Desai1, Robert Glynn1, Hemin Lee1, Michael Weinblatt1, Daniel H Solomon1 and Seoyoung Kim1, 1Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for cardiovascular (CV) events. While most RA patients use conventional disease-modifying antirheumatic drugs (DMARDs) such as…
  • Abstract Number: 2000 • ACR Convergence 2020

    Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine

    Mengdong He1, Ajinkya Pawar1, Rishi Desai1, Robert Glynn1, Hemin Lee1, Michael Weinblatt1, Daniel H Solomon1 and Seoyoung Kim1, 1Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Prior studies suggest an increased risk of venous thromboembolism (VTE) among patients with rheumatoid arthritis (RA). However, little is known about the comparative risk…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.